title: Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis.
authors.forename: Joseph R
authors.initials: JR
authors.lastname: Lutt
authors.forename: Mary L
authors.initials: ML
authors.lastname: Pisculli
authors.forename: Michael E
authors.initials: ME
authors.lastname: Weinblatt
authors.forename: Atul
authors.initials: A
authors.lastname: Deodhar
authors.forename: Kevin L
authors.initials: KL
authors.lastname: Winthrop
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology*; D058846:Antibodies, Monoclonal, Murine-Derived; D000917:Antibody Formation / Q000187:drug effects; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000187:drug effects; D005260:Female; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology*; D007155:Immunologic Factors / Q000009:adverse effects / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009165:Mycobacterium Infections, Nontuberculous / Q000276:immunology*; D009162:Mycobacterium avium / Q000302:isolation & purification; D019909:Mycobacterium kansasii / Q000302:isolation & purification; D009220:Myositis / Q000188:drug therapy* / Q000276:immunology; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D007155:Immunologic Factors; D000069283:Rituximab; D011241:Prednisone